RecruitingPhase 4NCT04427241

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness in Patients With Hemorrhagic Stroke: A Pilot Study


Sponsor

Konkuk University Medical Center

Enrollment

12 participants

Start Date

Jun 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke. Participants: patients with prolonged disorders of consciousness due to severe traumatic brain injury Intervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously or 100 ml normal saline, days 4-17, once/day, IV Comparison: cerebrolysin group versus control group Outcome: Coma Recovery Scale-revised, FDG-PET signal


Eligibility

Min Age: 19 YearsMax Age: 120 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cerebrolysin and a drug called Control for people with disorder of consciousness and hemorrhagic stroke. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCerebrolysin

30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously

DRUGControl

100 ml normal saline, days 4-17, once/day, IV


Locations(1)

Konkuk University Medical Center Research Coordinating Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04427241


Related Trials